Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAvMed 5-Tier Prescription Formulary Coverage & PA …
    Ask Trek AI about this page
    CurrentAvMedPolicy N/A

    Individual and Family Plans 5-Tier Prescription Drug Formulary (Non-Standard Plan)

    Customize your policy alerts

    Sign up for all AvMed policy alerts

    Know when AvMed releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines AvMed's 5-tier prescription drug formulary for individual and family plans, including coverage structure, prior authorization and exceptions procedures, and member/pharmacy requirements; affects AvMed members and in-network prescribers/pharmacies.

    Policy Summary
    PayerAvMed
    PolicyIndividual and Family Plans 5-Tier Prescription Drug Formulary (Non-Standard Plan)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionPrescriber must obtain prior authorization for certain drugs by submitting a completed drug authorization request form and supporting clinical documentation via fax to 1305-671-0200; urgent decisions in 24 hours and standard decisions in 1-3 business days.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5-tierformulary tier structure
    30-dayspecialty supply limit
    31-90 daymail-service range
    24h / 1-3dPA decision timelines

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    QL/PA/SP/STutilization types
    90-daymax mail supply

    Formulary Coverage Criteria

    Formulary Coverage Criteria and Exclusions

    High-level coverage stance, limits, and common exclusions for pharmacy benefits under the formulary.

    Retail coverage may include up to a 90-day supply (select plans); mail-service covers 31-90 day supply; specialty drugs limited to 30-day supply and must be obtained from a Plan Specialty Pharmacy.
    AvMed may change coverage criteria; coverage decisions are based on clinical guidelines and P&T review; the formulary is reference-only and does not guarantee payment.
    Certain drugs require prior authorization; urgent requests are typically decided within 24 hours and standard requests within 1–3 business days.
    Quantity limits apply per-drug and per-timeframe; prescribers must submit medical necessity documentation to request exceptions to QL limits.
    Non-formulary or quantity-exception requests require a statement of medical necessity and supporting clinical documentation via the prior authorization process.
    Common exclusions include OTC products (unless listed), experimental/foreign/unapproved medications, replacement meds for lost/stolen prescriptions (unless plan allows), fertility and sexual dysfunction products (unless specified), vitamins/minerals, nutritional supplements/medical foods, cosmetic products, appetite suppressants (unless specified), and compounded prescriptions except pediatric preparations; items covered under the medical benefit are excluded from the pharmacy benefit.
    When a brand is requested instead of an available approved generic, member cost-share may reflect Non-Preferred Brand copay plus any Brand Additional Charge consistent with plan policy.
    Certain preventive medications may be covered at $0 cost-share under ACA when criteria are met and the medication is listed as ACA in the formulary.

    Sample drug coverage nodes

    Drug-specific entries include drug name, Drug Tier, and Requirements / Limits (PA, QL, SP, ACA where applicable). Examples follow.

    fluconazole oral tablet 100 mg, 200 mg — Drug Tier 2; Requirements/Limits: QL (4 per 1 day).
    fluconazole oral tablet 150 mg — Drug Tier 2; Requirements/Limits: QL (4 per 30 days).
    flucytosine — Drug Tier 3; Requirements/Limits: PA.
    itraconazole oral capsule — Drug Tier 3; Requirements/Limits: QL (4 per 1 day).
    NOXAFIL ORAL SUSPENSION (delayed release) — Drug Tier 4; Requirements/Limits: PA; QL (1 per 1 day).
    posaconazole oral suspension — Drug Tier 3; Requirements/Limits: PA; QL (20 per 1 day).

    Tier-based coverage with utilization controls

    Formulary coverage is expressed via tier assignment and annotated requirements/limits. Specific coverage decisions are linked to these annotations.

    Drugs are assigned to tiers (examples observed: Tier 2, 3, 4, 5) which determine cost-sharing and indicate where utilization controls may apply.
    Requirement flags used in the formulary include PA (Prior Authorization), QL (Quantity Limit with amount/timeframe), SP (Specialty Pharmacy designation), LA (Limited Access/limited distribution), and ST (Step Therapy).
    Tier assignment combined with requirement flags governs coverage behavior — e.g., many Tier 5 specialty/oncology agents carry PA, SP, LA and QL annotations.

    Prior authorization and quantity limits

    Utilization management controls apply to specific drugs.

    Examples: DIFICID oral suspension — PA; 100 mL per fill. Fidaxomicin — PA; 20 tabs per fill. ARIKAYCE — noted with QL per day. Many drugs listed require PA and/or have QL as specified per formulation.

    Specialty pharmacy / limited distribution controls

    High-cost specialty and oncology drugs have layered controls.

    Many Tier 5 antineoplastic and immunosuppressant agents require specialty pharmacy (SP), may be limited distribution (LA), have quantity limits (QL), and require prior authorization (PA).
    Examples include IBRANCE, XALKORI, DASATINIB and numerous other oncology agents (PA; SP; QL as listed per product).

    Formulary entries with requirements and limits (partial)

    Coverage stance for listed drugs is expressed by formulary tier and explicit requirements/limits per drug/formulation.

    Drug entries include the Drug Tier and Requirements / Limits fields; requirements can include PA, SP, LA, QL and age-based PA constraints.
    Example: IBRANCE ORAL CAPSULE 125 MG — Drug Tier 5; Requirements/Limits = PA; SP; QL (1 per 1 day).
    Example: hydroxyurea — Drug Tier 2; Requirements/Limits = none listed.
    Example: tacrolimus oral capsule — Drug Tier 2; Requirements/Limits = SP (specialty).

    Formulary coverage with utilization controls

    Formulary entries list drug, tier, and any requirements or limits that govern coverage for that drug under the plan.

    VONJO — Drug Tier 5; Requirements/Limits: PA; SP; QL (4 per 1 day).
    XALKORI ORAL CAPSULE — Drug Tier 5; Requirements/Limits: PA; SP; QL (4 per 1 day).
    ZEJULA ORAL TABLET — Drug Tier 4; Requirements/Limits: PA; SP; LA; QL (1 per 1 day).
    Entries are illustrative; full formulary contains many additional per-product requirements and limits as shown throughout the listing.

    Formulary coverage entries (sample)

    Drugs are listed with a drug tier and Requirements / Limits that determine coverage conditions.

    baclofen oral tablet: 5 mg — Drug Tier 3; Requirements/Limits: QL (3 per 1 day); 10/20 mg strengths — Drug Tier 2; no QL listed for higher strengths in this extract.
    dantrolene oral capsule: 25/50 mg — Drug Tier 3; QL (3 per 1 day); 100 mg — Drug Tier 3; QL (4 per 1 day).
    VYVGART HYTRULO SUBCUTANEOUS — Drug Tier 5; Requirements/Limits: PA; SP; LA; QL (20 per 28 days).
    Aspirin products (multiple OTC strengths) are listed with ACA/OTC designation where applicable indicating preventive coverage in some cases.

    Formulary coverage entries and constraints

    Formulary entries indicate coverage tier and constraints; many products require prior authorization for specified age ranges and have quantity limits.

    ARISTADA intramuscular suspension (various presentations) — Drug Tier 3; Requirements/Limits: PA for Age <=17; QL (2.4 or 3.2 per 28 days) depending on presentation.
    Armodafinil formulations — Drug Tier 3; Requirements/Limits: QL varies by strength (1 per 1 day or 2 per 1 day).
    Asenapine maleate — Drug Tier 3; Requirements/Limits: PA; PA for Age <=17; QL (2 per 1 day).
    Clozapine (various strengths) — Drug Tier 3; Requirements/Limits: PA for Age <=17; QL varies by strength (examples shown).
    INVEGA injectables — Drug Tier 3; Requirements/Limits: PA for Age <=17; QL specified per product (examples provided).

    Formulary entries with requirements and limits (partial)

    Per-entry coverage stance is encoded via 'Drug Tier' and 'Requirements / Limits' fields; many products require prior authorization or have quantity limits.

    UZEDY subcutaneous suspension (multiple strengths) — Drug Tier 3; Requirements/Limits: PA for Age <=17; QL (fractional per 28 days as listed per strength).
    TRINTELLIX — Drug Tier 4; Requirements/Limits: PA; QL (1 per 1 day).
    Trazodone oral tablet 100/150/50 mg — Drug Tier 2; Requirements/Limits: QL (3 per 1 day).

    Specialty and anticoagulation agents

    Specialty and high-tier agents include additional controls such as SP, LA, and multi-day or annual QL limits.

    Many Tier 5 specialty products include PA and SP designations and may be LA (limited distribution); QL values vary and may be per day, per 28 days, or per 365 days as listed per product.
    Examples: ORENITRAM/UPTRAVI/CABLIVI/DOPTELET and similar agents — Drug Tier 5; Requirements/Limits: PA; SP; LA where noted; QL as specified (per day/365 days).
    Anticoagulation examples: rivaroxaban — Drug Tier 3; Requirements/Limits: QL (20 per 1 day) for certain formulations; REPATHA products — PA; QL per 28 days noted for PCSK9 injectables.

    Coverage criteria implied by formulary entries

    Formulary items include tier assignment and any applicable requirements or limits which govern coverage and dispensing.

    Drugs flagged with 'PA' require prior authorization before coverage is provided as listed (examples: HYMPAVZI PEN, MULPLETA, REPATHA products and many biologics).
    Drugs flagged with 'SP' must be obtained through a specialty pharmacy when designated (examples: many injectable biologics and specialty pens).
    Many entries include QL specifying maximum quantity per time period (examples: QL (4 per 28 days), QL (1 per 28 days), QL (0.5 per 63 days) etc.).
    Some topical agents list Step Therapy (ST) or age-based PA requirements where indicated (examples appear in dermatologic/topical sections).

    Formulary coverage entries and utilization constraints

    Formulary entries specify coverage tier and, when present, utilization management requirements.

    Lidocaine hcl mucous membrane solution 4% — Drug Tier 3; Requirements/Limits: none listed in this extract.
    Lidocaine topical adhesive patch 5% — Drug Tier 3; Requirements/Limits: QL (3 per 1 day).
    LULICONAZOLE, SULCONAZOLE topical solution, and tavaborole are listed with Requirements/Limits = PA in this segment.
    Penciclovir/acyclovir topical entries — Requirements/Limits: PA; QL (5 per 30 days) for some formulations as noted.

    CGM coverage with PA and quantity limits

    CGM devices and sensors

    DEXCOM G6 Receiver — Drug Tier 4; Requirements/Limits: PA; CGM designation; QL (1 per 365 days).
    DEXCOM G6 and G7 Sensors — Drug Tier 4; Requirements/Limits: PA; CGM; QL (3 per 30 days for sensors; G7 2-3 per 30 days depending on device).
    FREESTYLE LIBRE sensors/readers listed with PA; CGM; QL values (sensors 2 per 28-30 days; readers 1 per 365 days) depending on product.

    Insulin and pump supplies coverage with quantity limits

    Insulin products and delivery devices

    Multiple insulin products and pens are listed with a common QL of 100 units per 30 days; some higher-concentration presentations may require PA in addition to QL limits.
    OMNIPOD pods — Drug Tier 3; Requirements/Limits: QL (10 per 30 days); Intro kits QL (1 per 720 days).
    V-GO devices — Drug Tier 3; Requirements/Limits: QL (30 per 30 days).

    Specialty drugs requiring authorizations and specialty pharmacy

    Specialty/high-cost drugs and hormones

    Multiple specialty agents (examples: GALAFOLD, PALYNZIQ, STRENSIQ, VOXZOGO) — Drug Tier 5; Requirements/Limits: PA; SP; often LA; QL specified for many products.
    Some hormonal or orphan agents (e.g., mifepristone, miglustat, MYALEPT) — Drug Tier 4–5 with PA; SP; QL as noted where applicable.

    Partial coverage criteria nodes extracted from formulary listing

    Formulary coverage characterization (partial):

    Some agents are assigned to low tiers with ACA/OTC designations (e.g., certain statins, contraceptives), while others are tiered higher and require utilization controls.
    Utilization management mechanisms across the formulary include PA, QL, SP, LA and ST; many entries show combinations of these controls per product.
    Step Therapy (ST) is applied to selected products (examples shown in GI and other therapeutic classes).

    Coverage criteria by drug group

    Coverage stance for listed drugs varies by tier and may include authorization or limits.

    Gastrointestinal and acid suppression therapies are tiered with QL and occasional PA for pediatric formulations (examples: esomeprazole, lansoprazole, omeprazole with QL/age PA rules).
    Biotechnology drugs (e.g., ARANESP, EPOGEN, biosimilars) are commonly PA; SP and often have QL per period as listed per product.
    Vaccines and immunizations: many items are designated ACA (preventive coverage) and some have age-based PA or QL notes in the listing.
    Rheumatology/biologic agents are frequently Tier 5 and require PA; SP; and have QL (per 28 days or other timeframes) as shown in entries (e.g., ACTEMRA, ENBREL, ADALIMUMAB biosimilars).

    Selected coverage flag examples

    Coverage stance is indicated by drug tier plus any requirements/limits; specific clinical criteria are not included in this fragment.

    Teriparatide subcutaneous pen injector 20 mcg/dose — Drug Tier 4; Requirements/Limits: PA; SP; QL (1 per 28 days).
    ACTEMRA products — Drug Tier 5; Requirements/Limits: PA; SP; QL (3.6 per 28 days).
    ADALIMUMAB-ADBM biosimilar — Drug Tier 5; Requirements/Limits: PA; SP; QL (2 per 28 days).
    Risedronate oral tablet 150 mg — Drug Tier 3; Requirements/Limits: QL (1 per 28 days).
    Milnacipran oral tablet — Drug Tier 3; Requirements/Limits: ST; QL (2 per 1 day).

    Preventive and OTC designations

    Many contraceptives and related OB/GYN products are marked ACA (preventive coverage) and/or OTC where applicable.

    Examples

    • camila — Drug Tier 2; Designation: ACA.
    • levonorgestrel — Drug Tier 9; Designation: ACA; OTC.
    • after pill — Drug Tier 9; Designation: ACA; OTC.
    Multiple oral contraceptives across the formulary are listed with ACA designation indicating preventive coverage where applicable to the member's benefits.

    Coverage with utilization management

    Select drugs are covered subject to utilization management controls

    CYSTADROPS — Drug Tier 5; Requirements/Limits: PA; SP; QL (20 per 28 days).
    OXERVATE — Drug Tier 5; Requirements/Limits: PA; SP; QL (56 per 720 days).
    NUCALA, ADEMPAS, ORLADEYO and similar specialty agents — Drug Tier 5; Requirements/Limits: PA; SP; LA; QL as specified per drug.
    AUVI-Q (auto-injector) — Drug Tier 4; Requirements/Limits: PA (AUVI-Q requires PA as noted).
    Epinephrine auto-injectors (various) — Tiering and QL noted for some strengths; QL/PA apply per listing.

    Ophthalmology coverage (selected)

    Common ophthalmic and topical agents listed with tier assignments; many are lower-tier and OTC where noted

    Ophthalmic antibiotics: bacitracin ophthalmic — Drug Tier 3; bacitracin-polymyxin b — Drug Tier 2; ciprofloxacin ophthalmic — Drug Tier 4 (or Tier 2 depending on formulation); many topical ophthalmic antibiotics are covered with tiering and occasional QL.
    Ophthalmic anti-inflammatories: ketorolac ophthalmic — Drug Tier 2; bimatoprost ophthalmic drops — Drug Tier 3; entries reflect tiered coverage and, where noted, OTC designation for select nonprescription products.
    Selected ophthalmic specialty products: CYSTADROPS, CYSTARAN, OXERVATE, XDEMVY are Tier 5 specialty ophthalmic drugs and require PA; SP; and have specified QL values in the formulary.

    Formulary Coding and Abbreviations

    Formulary Definitionsmixed
    Definitions for Brand Medication, Generic Medication, Participating Pharmacy, Prescription Medication, Prior Authorization
    Formulary tier abbreviationsmixed
    1Preferred Generic
    2Generic
    3Preferred Brand
    4Non-Preferred Brand
    5Specialty Drugs
    9Zero Cost Share Preventive Drugs
    Observed drug tier groupingsmixed
    Tier 2Many generic and commonly used antibiotics (e.g., cefadroxil, cephalexin 250/500 mg, doxycycline, rifampin) are listed as Drug Tier = 2.
    Tier 3Selected formulations or higher-strength products and some agents (e.g., cefixime, erythromycin delayed release, vancomycin oral capsule) are listed as Drug Tier = 3.
    Tier 4Certain specialized antiinfectives and others (e.g., DIFICID suspension, ALINIA suspension) are listed as Drug Tier = 4.
    Tier 5Many specialty and antineoplastic agents are listed as Drug Tier = 5 (e.g., ARIKAYCE, CAYSTON, numerous oncology agents).
    Formulary tiersmixed
    Formulary tier assignments observed (examples: Tier 2, Tier 3, Tier 4, Tier 5)
    Formulary tiers in this excerptmixedCovered
    Tier 2Lower formulary tier for certain common meds (examples: carbamazepine tablet, gabapentin, memantine, tizanidine).
    Tier 3Mid formulary tier for various anticonvulsants and specialty oral formulations (examples: brivaracetam, lacosamide, perampanel).
    Tier 4Higher-cost tier (examples: ZEJULA listed as Tier 4; some migraine therapies Tier 4).
    Tier 5Highest tier for many specialty/expensive agents (multiple examples across chunks).
    Formulary requirement codesmixed
    PAPrior Authorization required
    QLQuantity Limit (specific amounts per time unit)
    STStep Therapy
    SPSpecialty Pharmacy
    LALimited Access
    ACA; OTCAffordable Care Act / Over-the-counter designation
    billing/coding notesmixed
    NDC or other billing codes are not included in these chunks; only drug names, tiers, and requirement descriptors (PA, QL, ST, SP) are listed.
    Formulary tier & utilization flagsmixed
    Formulary entries reference tier levels (1-5) and utilization flags (PA, QL, SP, ST, LA) rather than billing/coding codes in this excerpt.
    Formulary drug tier and requirement annotations (placeholder)mixed
    No codes listed
    Formulary tier assignments (names only)mixed
    Drug tier assignments (Tier 2-5) and drug names as listed; no formal billing/CPT/HCPCS/NDC codes provided in this extract.
    CGM devices and sensorsNDC | mixed
    DEXCOM G6 RECEIVER - PA; CGM; QL (1 per 365 days)
    DEXCOM G6 SENSOR - PA; CGM; QL (3 per 30 days)
    DEXCOM G7 SENSOR - PA; CGM; QL (3 per 30 days)
    FREESTYLE LIBRE 14 DAY SENSOR - PA; CGM; QL (2 per 28 days)
    Insulin productsNDC | mixed
    HUMALOG KWIKPEN INSULIN PEN 100 UNIT/ML - Requirements / Limits = 100 units per 30 days (some formulations require PA).
    HUMALOG JUNIOR KWIKPEN U-100 - Requirements / Limits = 100 units per 30 days.
    OMNIPOD 5 PODS (GEN 5) - Requirements / Limits = QL (10 per 30 days); Intro kits QL (1 per 720 days).
    V-GO devices (V-GO 20/30/40) - Requirements / Limits = QL (30 per 30 days).
    Formulary tier coding format (document-specific)mixed
    Drug Name, 1 = Drug Tier. Drug Name, 2 = Requirements / Limits (document presents tiers and requirements in this two-column format).
    Formulary tiersmixed
    Formulary tier numbers (1-5 and 9) applied per drug line as shown in the listing (examples across therapeutic areas).
    Codes absent in this partmixed
    No explicit billing or NDC/CPT/HCPCS codes are listed in this section; only drug names, tiers, and requirement flags are provided.
    Formulary tier and utilization management flags (document-level)mixed
    PAPrior Authorization
    SPSpecialty Pharmacy
    QLQuantity Limit
    LALimited Access
    STStep Therapy
    ACA; OTCACA (preventive)/OTC designations where noted
    Quantity limits / supply limits — general
    Specialty drug supplySpecialty medications are limited to a 30-day supply (dispensed by a participating specialty pharmacy)
    Mail-service supplyMail-service supplies may be dispensed for 31–90 days depending on plan
    Retail supply (select plans)Retail coverage may include up to a 90-day supply for select plans
    Quantity limit exceptions

    Prior Authorization and Provider Requirements

    Prior Authorization

    Obtain prior authorization using AvMed drug authorization form

    Prescriber must submit a completed drug authorization request form and supporting clinical documentation (lab values, prescription history, statement of medical necessity or other pertinent information) to AvMed via fax to 1305-671-0200; urgent PA decisions typically within 24 hours and standard decisions within 1–3 business days.

    • Use the pharmacy drug authorization request form available at https://www.avmed.org/prescriptions/ or https://www.avmed.org/forms/provider.
    • Include labs, prescription history, and statement of medical necessity as needed to satisfy coverage guidelines.
    Documentation Required

    Submit medical necessity statement for QL or non‑formulary requests

    If a prescription exceeds a listed quantity limit or a non-formulary medication is requested, the prescriber must submit a statement of medical necessity and supporting documentation through the prior authorization process to request an exception.

    Key Terms and Abbreviations

    Brand Medication — definition
    Brand MedicationA prescription medication manufactured and sold under a name or trademark or identified as Brand by AvMed's PBM
    Brand Additional ChargeAdditional charge if member/prescriber chooses brand when an approved generic exists (difference between brand and generic cost)
    Formulary Drug ListThe multi-tiered listing of preferred medications based on clinical efficacy, safety, and cost used to determine copay levels
    Generic Medication — definition
    Generic MedicationMedication with the same active ingredient as a brand medication or identified as generic by AvMed's PBM; FDA-approved generics are equivalent to brand-name products
    Therapeutic equivalenceGenerics contain identical active ingredients, same indication, strength and dosage form as brand-name products
    Policy Summary
    PayerAvMed
    PolicyIndividual and Family Plans 5-Tier Prescription Drug Formulary (Non-Standard Plan)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionPrescriber must obtain prior authorization for certain drugs by submitting a completed drug authorization request form and supporting clinical documentation via fax to 1305-671-0200; urgent decisions in 24 hours and standard decisions in 1-3 business days.
    SourceLink
    On This Page
    Formulary Coverage CriteriaFormulary Coding and AbbreviationsPrior Authorization and Provider RequirementsKey Terms and Abbreviations
    VIVJOA — Drug Tier 4; Requirements/Limits: PA; QL (18 per 84 days).
    PAXLOVID ORAL TABLETS, DOSE PACK 150 — Drug Tier 3; Requirements/Limits: QL (40 per 365 days).
    MAVYRET ORAL TABLET — Drug Tier 2; Requirements/Limits: PA; SP; QL (3 per 1 day).
    EPCLUSA — Drug Tier 5; Requirements/Limits: PA; SP; QL (1 per 1 day).
    HARVONI — Drug Tier 5; Requirements/Limits: PA; SP.
    cefaclor oral capsule — Drug Tier 2; Requirements/Limits: none listed.
    cephalexin oral capsule 250 mg, 500 mg — Drug Tier 2; Requirements/Limits: none listed.
    fidaxomicin — Drug Tier 3; Requirements/Limits: PA; QL (20 tabs per fill).
    If a prescription exceeds a listed quantity limit, prescriber must submit a medical necessity statement and request a prior authorization
    Quantity limits examples — per-drug
    Fluconazole tabletsQL (4 per 1 day) for 100 mg/200 mg tablets; QL (4 per 30 days) for 150 mg tablets
    DIFICID (fidaxomicin/formulation examples)DIFICID oral suspension: PA; 100 mL per fill; fidaxomicin: PA; 20 tabs per fill
    PAXLOVID dose packPAXLOVID oral tablets, dose pack 150: QL (40 per 365 days); 300-pack QL (60 per 365 days)
    Quantity limits examples — assorted
    DIFICID oral suspensionPA; 100 mL per fill
    fidaxomicinPA; 20 tabs per fill
    ARIKAYCE / TOBI PODHALER examplesARIKAYCE example QL (8.4 per 1 day); TOBI PODHALER QL (224 per 28 days)
    Quantity limits examples — common QL values
    KISQALI dosing examplesQL (21 per 28 days) for 200 mg/day; QL (42 per 28 days) for 400 mg/day; QL (63 per 28 days) for 600 mg/day
    AlmotriptanQL (12 per 30 days)
    Sumatriptan formulationsExamples include QL values such as 6, 12 or 18 per 30 days depending on formulation
    Quantity limits examples — timeframe patterns
    Per day limitsExamples include QL (1 per 1 day), QL (2 per 1 day), QL (3 per 1 day)
    Per 28-day limitsExamples include QL (21 per 28 days), QL (42 per 28 days), QL (126 per 28 days)
    Per 365-day limitsExamples include QL (9 per 365 days), QL (45 per 365 days), QL (60 per 365 days)
    Quantity limits examples — various
    Triptan familyQL examples: rizatriptan QL (12 per 30 days); zolmitriptan QL (12 per 30 days); sumatriptan QL (6-18 per 30 days depending on formulation)
    Naproxen examplesQL (6 per 1 day); other strengths QL (4 per 1 day or 3 per 1 day)
    Antipsychotic (clozapine)Clozapine QL examples: 9 per 1 day (100 mg), 4.5 per 1 day (200 mg), 3 per 1 day (25/50 mg)
    Quantity limit examples — sample entries
    ZURZUVAE examplesQL (28 per 14 days) or QL (14 per 14 days) depending on strength; PA; SP
    UZEDY (injectable) pediatricsPA for Age <=17; QL examples: 0.14 per 28 days, 0.21 per 28 days
    KOMZIFTI / KOSELUGOQL examples include 3 per 1 day (KOMZIFTI) and KOSELUGO QL (8 per 1 day or 4 per 1 day depending on strength)
    Quantity limit examples — sample QL entries
    Malathion / PermethrinQL (120 per 30 days)
    IMCIVREE (anorexiant)PA; SP; QL (9 per 30 days)
    SANTYL (topical enzyme)QL (2 per 720 days)
    Example quantity limits — assorted QLs
    High-cost oncology agentsMany require PA; SP; LA and have QL such as 1 per 1 day, 3 per 1 day, 4 per 1 day depending on product
    Tobramycin inhalationSP; QL (224 per 28 days) or QL (10 per 1 day) depending on formulation
    IBRANCEPA; SP; QL (1 per 1 day)
    CGM receiver frequency
    CGM receiver frequencyDEXCOM G6/G7 receiver: QL (1 per 365 days)
    CGM sensor frequencyDEXCOM G6/G7 sensors: QL (3 per 30 days); FREESTYLE LIBRE sensors: QL (2 per 28 days)
    CGM transmitter frequencyDEXCOM G6 transmitter: QL (1 per 68 days)
    CGM sensor frequency
    DEXCOM sensorsDEXCOM G6 sensor: QL (3 per 30 days); DEXCOM G7 sensor: QL (3 per 30 days)
    FreeStyle Libre sensors/readersFreeStyle Libre 14 day sensor: QL (2 per 28 days); Libre 2 sensor: QL (2 per 28-30 days)
    Freestyle readersReaders QL (1 per 365 days) and some are ACA/OTC designated
    Insulin units limit
    Standard insulin unit limitMany insulin products listed with a common limit of 100 units per 30 days
    Humalog kwikpen examplesHUMALOG KWIKPEN and many Humalog mixes: 100 units per 30 days
    Concentrated insulin and PASome concentrated formulations note PA plus the 100 units per 30 days limit
    Quantity limits examples — assorted per-product
    PPI examplesEsomeprazole QL (2 per 1 day); lansoprazole QL (2 per 1 day)
    Biotech QLsExamples include QL (2 per 1 day), QL (30 per 365 days), QL (224 per 365 days) for specific biotech products
    Palforzia levelsPalforzia maintenance/levels have QL ranges such as 7–90 per 365 days depending on level
    Quantity limit examples — per-drug QLs
    Zyprexa Relprevv (IM)QL examples: 2 per 28 days or 1 per 28 days depending on dose; PA for pediatric age limits
    Venlafaxine ERVenlafaxine ER QL (1–3 per 1 day) depending on strength
    XTAMPZA ER / extended-releaseXTAMPZA ER QL (6 per 1 day); some ER products require PA
    Common quantity limits examples — patterns
    Common per-day patternMany specialty biologics show per-day limits such as QL (1 per 1 day), QL (2 per 1 day), QL (3 per 1 day)
    Per-28-day patternCommon values include QL (1 per 28 days), QL (2 per 28 days), QL (4 per 28 days), QL (12 per 28 days)
    Annual/365-day patternExamples include QL (45 per 365 days), QL (55 per 365 days), QL (90 per 365 days)
    Examples of quantity limits — ophthalmic/specialty
    CYSTADROPSPA; SP; QL (20 per 28 days)
    OXERVATEPA; SP; QL (56 per 720 days)
    RUCONESTPA; QL (2 per 28 days)
    Example quantity limits — devices & supplies
    CGM receivers/readersDEXCOM G6/G7 and FreeStyle readers: QL (1 per 365 days)
    CGM sensorsDEXCOM G6/G7 sensors QL (3 per 30 days); FreeStyle Libre sensors QL (2 per 28–30 days)
    Pump supplies (pods)OMNIPOD pods QL (10 per 30 days); intro kits QL (1 per 720 days)
    • For QL exceptions: provide a statement of medical necessity and request prior authorization per the Prior Authorization Process.
    • For non‑formulary requests: provide medical records/prescription claims history showing medical necessity, contraindications to all formulary alternatives, or therapeutic failure of adequate trials of formulary alternatives.
    Step Therapy

    Provide documentation for step therapy / CED exceptions

    Step therapy and Clinically Equivalent Drug (CED) rules require clinical documentation and will have prior authorization when applicable; medications labeled CED on the formulary will also require PA.

    • If a member cannot use required first- or second-line therapy for medical reasons, prescriber should request prior authorization with supporting documentation.
    • CED-labeled medications require submission of clinical documentation establishing medical necessity over comparable formulary alternatives.
    Documentation Required

    Member-initiated prior authorization permitted

    Members may initiate a prior authorization by contacting AvMed Member Engagement (number on member ID card) or via the prescriptions section of AvMed's website; the member should provide prescriber contact information and pertinent details to the representative.

    • Members can also start the process by logging into https://www.avmed.org/prescriptions/#list-of-covered-drugs and clicking the 'Prescriptions' link.
    Prior Authorization

    Follow PA/QL/ST/SP utilization management flags on formulary entries

    Prior Authorization (PA), Quantity Limit (QL), Step Therapy (ST) and Specialty (SP) flags on formulary entries require adherence to those controls; PA must be obtained before coverage for drugs marked PA.

    • Check each formulary line for requirement flags (PA, QL, ST, SP, LA) before prescribing or dispensing.
    • Drugs marked PA will not be covered unless prior authorization is approved.
    Prior Authorization

    Obtain PA when formulary entry shows PA + QL (examples provided)

    Some drugs require both prior authorization and specific quantity limits per fill (example: DIFICID oral suspension requires PA and is limited to 100 mL per fill; fidaxomicin requires PA and is limited to 20 tablets per fill).

    • Verify both PA requirement and QL value in the formulary entry and submit PA request citing the specific formulation and quantity limit.
    • Include prescription details that match the QL (e.g., mL per fill or tablets per fill) when requesting authorization.
    Prior Authorization

    Request PA and use specialty pharmacy for oncology/limited‑distribution products

    High‑cost oncology and immunosuppressant therapies are frequently flagged PA and SP, and may also have Limited Availability (LA); obtain PA and arrange specialty pharmacy dispensing when indicated.

    • Examples include many Tier 5 antineoplastic agents listed with PA; SP; LA and specified QL values (e.g., IBRANCE, VITRAKVI, XALKORI).
    • Contact AvMed/Customer Service for LA details and specialty pharmacy routing.
    Prior Authorization

    Adhere to per‑product PA/SP/QL/LA controls shown on formulary entries

    Many formulary entries include PA, SP, QL and sometimes LA controls; prescribers must follow the per‑product Requirements / Limits shown on the formulary and obtain authorization or use specialty channels as required.

    • Confirm per‑product controls (PA/SP/LA/QL) prior to prescribing; examples in the formulary show these flags across many entries.
    • Where SP is indicated, dispense through a participating specialty pharmacy as required.
    Note

    Check utilization control flags (PA / SP / LA / QL / ST) on each drug line

    Formulary entries use standardized flags (PA, SP, LA, QL, ST) — verify the annotation on each drug line and follow the indicated prior authorization, specialty pharmacy, step therapy, or quantity‑limit procedures.

    • These flags determine whether PA, specialty dispensing, limited distribution, or step therapy are required before coverage.
    • Use the formulary legend at the beginning of the table to interpret abbreviations if needed.
    Prior Authorization

    Obtain PA or follow utilization controls shown in Requirements / Limits

    Many products across the formulary require some combination of PA, QL, ST, SP or LA — prescribers must review the Requirements / Limits column and request authorization or follow step therapy pathways as specified.

    • Examples in the listing include age‑based PA and QL values; adhere strictly to the entry details when requesting exceptions.
    • If symbols/abbreviations are unclear, refer to the table legend at the start of the formulary.
    Prior Authorization

    Submit PA for specialty/ER products that list PA and QL

    Certain extended‑release and specialty injectable products have explicit quantity limits and may require prior authorization (examples: SUBLOCADE, XTAMPZA ER — check each formulary line for PA and stated QL).

    • XTAMPZA ER is shown with QL (6 per 1 day) and PA where indicated; confirm product‑specific rules before prescribing.
    • For extended‑release or ER specialty products, include formulation details in PA requests.
    Prior Authorization

    Follow formulary entry PA and age‑based QL rules (e.g., ARISTADA)

    Numerous formulary entries indicate PA requirements and quantity limits for specific products and age groups (e.g., ARISTADA injectables require PA for Age ≤17 and list QL values); prescribers must follow those entry‑specific authorization rules.

    • When age‑based PA is shown, include the patient age and any supporting pediatric/age‑specific documentation in the PA request.
    • Match the requested dose/presentation to the formulary line when submitting the authorization.
    Step Therapy

    Document step therapy trials and follow LA instructions for specialty products

    Specialty products may also be subject to step therapy and limited access controls; where ST or LA appear (e.g., HETLIOZ, LUMRYZ, SPRAVATO), prescribers must document prior trials or obtain PA per the formulary requirements.

    • If step therapy applies, document trials of required agents or provide medical justification in the PA request.
    • For LA products, contact AvMed/Customer Service for dispensing location details and PA instructions.
    Note

    Consult per‑drug Requirements / Limits and submit PA/documentation as listed

    The formulary frequently annotates entries with PA, QL, SP, LA and ST — prescribers must consult the Requirements / Limits column for each drug and submit prior authorizations or documentation when those controls are present.

    • Provide clinical rationale and required supporting materials per the Prior Authorization Process when controls are present.
    • Do not assume coverage if a formulary entry includes a PA or QL flag.
    Prior Authorization

    Include age and age‑specific justification for PA when entry lists age restrictions

    Certain products include age‑based prior authorization restrictions (e.g., PA for Age ≤17); prescribers must include patient age and age‑specific justification when requesting authorization.

    • Examples: ARISTADA and multiple injectable products list PA for specific age ranges — include age and relevant clinical notes in PA submission.
    Prior Authorization

    Request PA and coordinate specialty pharmacy for biologics/dermatologic biologics

    Multiple high‑cost biologic and dermatologic agents are listed with PA, often SP and QL (examples: HYMPAVZI PEN, MULPLETA, REPATHA products); prescribers must request PA and arrange specialty pharmacy dispensing where indicated.

    • When QL is specified, include the requested quantity and timeframe in the PA submission.
    • For SP‑flagged products, ensure prescription is routed to a participating specialty pharmacy per AvMed guidance.
    Prior Authorization

    Obtain PA for formulary topical products marked PA (examples provided)

    Topical antifungals and antivirals may require prior authorization (examples: LULICONAZOLE, SULCONAZOLE TOPICAL SOLUTION, tavaborole are listed as PA); submit PA per the Prior Authorization Process for these entries.

    • Penciclovir and acyclovir topical entries show PA and QL (e.g., QL 5 per 30 days) — include quantity details in PA requests.
    Prior Authorization

    Submit PA and follow SP/LA/Q L rules for high‑tier specialty products (EMPAVELI example)

    Some specialty/high‑tier products (e.g., EMPAVELI) are marked PA; SP; LA and include specific QL values (EMPAVELI QL 160 per 28 days); prescribers must request PA and follow specialty/limited distribution procedures.

    • Include the exact product presentation and requested quantity (per the QL) in the PA submission.
    • For LA products, contact AvMed for dispensing instructions and specialty pharmacy routing.
    Documentation Required

    Request QL exceptions via PA when prescribed quantity exceeds formulary QL

    Some formulary entries list specific QL values (e.g., penciclovir PA; QL 5 per 30 days); prescribers must request a QL exception via PA with a medical necessity justification if the prescribed quantity exceeds the stated limit.

    • When requesting a QL exception, state the quantity requested, clinical rationale, and duration of therapy.
    Documentation Required

    Include device model and clinical data when requesting PA for CGM devices/sensors

    Continuous glucose monitoring devices and supplies are designated CGM and require prior authorization and have quantity limits (e.g., DEXCOM G6 receiver: PA; CGM; QL 1 per 365 days; sensors/transmitters have specific QLs); include device type and necessary clinical data in PA requests.

    • Dexcom examples: G6 receiver QL 1 per 365 days; G6 sensor QL 3 per 30 days; G7 sensor QL 2 per 30 days — include device model in the PA.
    • Provide diabetes management data or clinical justification supporting CGM coverage.
    Billing Rule

    Honor insulin QLs (100 units/30 days common) and obtain PA when required

    Insulin products and insulin delivery devices generally have quantity limits (commonly 100 units per 30 days) and some formulations require prior authorization; confirm QL on the formulary and include unit limits in the PA or prescription.

    • Many insulin pens and vials are listed with a 100 units per 30 days QL; certain concentrated pens may require PA in addition to the QL.
    • For pump supplies and starter kits, note the specified QL (e.g., intro kits 1 per 720 days; pods 10 per 30 days).
    Prior Authorization

    Submit PA with dose/quantity details for GLP‑1 and related agents (MOUNJARO/OZEMPIC/RYBELSUS examples)

    For select specialty diabetes and obesity medications, PA and QL requirements are specified (examples: MOUNJARO: PA; QL 2 per 28 days; OZEMPIC oral tablet 1.5 mg: PA; QL 30 per 365 days; RYBELSUS formulations list PA and product‑specific QLs).

    • Include product strength, dosing frequency and requested quantity in the PA submission for GLP‑1 and related agents.
    • Check each formulation's QL timeframe (per 28 days vs per 365 days) when requesting authorization.
    Prior Authorization

    Request PA and route biologics to specialty pharmacy; include prior therapy history

    Many biologics and other specialty agents require prior authorization and are dispensed via specialty pharmacy with quantity limits (examples: ENTYVIO PEN, CIMZIA, SKYRIZI; RELISTOR subcutaneous products list PA and QL values).

    • When prescribing biologics, include indication, prior therapies tried, and requested dosing schedule in the PA.
    • Route prescriptions for SP‑flagged products to a participating specialty pharmacy per AvMed instructions.
    Prior Authorization

    Include clinical/lab data when seeking PA for biotechnology and rheumatology biologics

    Many biotechnology products list PA and specialty pharmacy requirements and often include quantity limits (per day, per 28/63/365 days); prescribers must follow the entry‑specific PA/QL/SP rules for these agents.

    • Examples include erythropoiesis‑stimulating agents and rheumatology biologics with PA; SP; QL (values vary by product).
    • Provide necessary lab data, diagnoses, and prior medication trials in PA submissions for biotechnology drugs.
    Note

    Comply with combined utilization controls (PA / SP / ST / QL) for specialty/biologic drugs

    Utilization controls across many specialty and biologic agents include PA, SP, ST and QL flags; prescribers must check and comply with each control type listed for the medication.

    • Step therapy (ST) may require documented trials of specified agents prior to coverage of the requested drug.
    • Quantity limits must be respected or justified via a QL exception request through PA.
    Prior Authorization

    Request PA and include ophthalmology documentation for ophthalmic specialty drugs (CYSTADROPS/OXERVATE examples)

    Select ophthalmic specialty drugs require PA and specialty pharmacy handling and specify QLs (e.g., CYSTADROPS PA; SP; QL 20 per 28 days; OXERVATE PA; SP; QL 56 per 720 days); include ophthalmic formulation and quantity in the PA request.

    • For ocular biologics and specialty drops, attach ophthalmology notes and prior treatments to the PA.
    • Confirm the QL timeframe (per 28 days vs per 720 days) and request exceptions only when clinically justified.
    Prior Authorization

    Submit PA with clinical evidence for pulmonary/biologic therapies and follow SP/LA rules

    Multiple specialty pulmonary and systemic biologic therapies (e.g., ADEMPAS, NUCALA, ORKAMBI, PULMOZYME) are listed with PA; SP; LA and QL controls — prescribers must request prior authorization, coordinate specialty dispensing, and provide required clinical documentation.

    • Include disease‑specific objective data (e.g., pulmonary function tests) and prior treatment history in PA submissions for pulmonary biologics.
    • For LA products, confirm dispensing source and follow specialty pharmacy routing instructions.
    Denial Risk

    Obtain PA for AUVI‑Q and check PA/QL for epinephrine auto‑injectors

    Some auto‑injector products have formulary tier assignments and may require prior authorization (AUVI‑Q is listed as PA); verify the auto‑injector line and obtain PA where the formulary requires it.

    • AUVI‑Q injection auto‑injector 0.1 mg/0.1 mL is explicitly listed with Requirements = PA — submit PA accordingly.
    • Epinephrine auto‑injectors have tiering and quantity guidance; confirm QL and PA on the formulary line before dispensing.
    Note
    Formulary roleGenerics are commonly placed on lower formulary tiers to encourage use
    Specialty Medication — definition
    Specialty MedicationMedications classified by AvMed as specialty, generally for complex or ongoing conditions; must be prescribed by a medical provider and dispensed by a participating specialty pharmacy; limited to a 30-day supply
    Dispensing channelOften required to be dispensed through participating specialty pharmacies
    Supply limitStandard specialty supply limit is 30 days
    Prior Authorization — definition
    Prior AuthorizationProcess requiring approval from AvMed before dispensing certain prescription drugs per AvMed's guidelines; ordering prescriber must obtain approval
    Decision timelinesUrgent decisions typically within 24 hours; standard decisions within 1–3 business days
    DocumentationPrescriber must submit completed drug authorization form and supporting clinical documentation
    Step Therapy — definition
    Step TherapyProcess that requires trial of one or more first- or second-line medications before covering certain drugs; exceptions may be granted via prior authorization if medically necessary
    CED noteClinically Equivalent Drugs (CED) labeled medications will have a prior authorization requirement when applicable
    PurposeUsed to promote safe, effective and cost-efficient prescribing
    PA — abbreviation
    PA (abbrev)Prior Authorization — requires approval before filling; otherwise drug may not be covered
    QL (abbrev)Quantity Limit — limits amount of drug covered for a specified time period
    ST (abbrev)Step Therapy — requires trying specified drugs first before coverage of another drug
    QL — abbreviation
    QL (abbrev)Quantity Limit — maximum quantity per prescription and/or time period for one copay or coinsurance
    ExamplesShown per-day, per-28 days, per-30 days, or per-365 days in formulary entries
    Exception processPrescriber must request prior authorization with medical necessity when exceeding QL
    ST — abbreviation
    ST (abbrev)Step Therapy — see Step Therapy definition; requires trial of specified drugs first
    ApplicationApplied to selected drugs as indicated in Requirements / Limits column
    ExceptionExceptions via prior authorization if medically necessary
    SP — abbreviation
    SP (abbrev)Specialty Pharmacy — designation for specialty drugs that often require dispensing through a participating specialty pharmacy
    Associated controlsOften accompanied by PA, LA and QL requirements
    Supply limitTypically limited to a 30-day supply
    Formulary tier codes
    Tier 1Preferred Generic
    Tier 2Generic
    Tier 3Preferred Brand
    Tier 4Non-Preferred Brand
    Tier 5Specialty Drugs
    Tier 9Zero Cost Share Preventive Drugs
    Drug Tier — definition
    Drug Tier (definition)Numeric tier indicating the formulary placement for the listed medication (e.g., 1–5; 9 for preventive)
    ImpactTier determines member cost-sharing and formulary placement
    UsageAssigned per drug/formulation line in the formulary table
    Requirements / Limits abbreviations
    PAPrior Authorization — approval required before dispensing
    QLQuantity Limit — specific amount per defined time window (per day/28/30/365 days)
    SPSpecialty Pharmacy — designation that may require specialty dispensing and additional controls
    Common requirement abbreviations
    PA (short)Prior Authorization — requires approval before coverage
    SP (short)Specialty Pharmacy — specialty dispensing requirement
    QL (short)Quantity Limit — maximum quantity allowed over a specified time window
    Symbols/Abbreviations — table legend
    PA symbolIndicates prior authorization requirement; see beginning of table for legend
    QL symbolIndicates quantity limit with amount and time period (e.g., 3 per 1 day; 28 per 365 days)
    ST / SP / LAST = Step Therapy; SP = Specialty Pharmacy; LA = Limited Availability — defined in the table legend
    Formulary abbreviations
    Formulary abbreviations summaryQL = Quantity Limit; PA = Prior Authorization; ST = Step Therapy; SP = Specialty Drug
    ACA / OTCACA indicates preventive coverage under the Affordable Care Act; OTC indicates over-the-counter designation
    LALimited Availability — may be available only at certain pharmacies
    Continuous Glucose Monitoring (CGM) — note
    CGM designationContinuous Glucose Monitoring (CGM) items are designated 'CGM' in the table and require prior authorization and have quantity limits
    CGM QL examplesReceivers/readers QL (1 per 365 days); sensors QL (2–3 per 28–30 days) depending on device
    CGM PA requirementItems marked CGM require prior authorization as noted in Requirements / Limits
    PA / SP / QL — usage
    Abbreviation groupPA / SP / QL commonly appear together in formulary entries to indicate Prior Authorization, Specialty Pharmacy, and Quantity Limit
    LA and STLA (Limited Availability) and ST (Step Therapy) also used as needed per product
    ACA/OTC flagsACA and OTC designations applied where preventive or over-the-counter status applies